PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

被引：0
|
作者：
McDonald, F. [1 ]
Mornex, F. [2 ]
Garassino, M. C. [3 ]
Filippi, A. R. [4 ,5 ]
Christoph, D. [6 ]
Haakensen, V. D. [7 ]
Agbarya, A. [8 ]
Van den Heuvel, M. [9 ]
Vercauter, P. [10 ]
Chouaid, C. [11 ]
Pichon, E. [12 ]
Siva, S. [13 ]
Steinbusch, L. [9 ]
Peretz, I. [14 ]
Solomon, B. [15 ]
Decoster, L. [16 ]
Sawyer, W. [17 ]
Allen, A. [18 ]
Licour, M. [19 ]
Girard, N. [20 ,21 ]
机构：
[1] Royal Marsden Hosp NHS Fdn Trust, Lung Unit, London, England
[2] Ctr Hosp Univ Lyon, Dept Radiat Oncol, Lyon, France
[3] Ist Nazl Tumori Milano Fdn IRCCS, Div Med Oncol, Milan, Italy
[4] Fdn IRCCS Policlin San Matteo, Dept Radiat Oncol, Pavia, Italy
[5] Univ Pavia, Pavia, Italy
[6] Evangel Kliniken Essen Mitte, Dept Med Oncol, Evangel Huyssens Stiftung, Essen, Germany
[7] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[8] Bney Zion Med Ctr, Dept Oncol, Haifa, Israel
[9] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[10] Onze Lieve Vrouw Ziekenhuis Aalst, Dept Pneumol, Aalst, Belgium
[11] CHI Creteil, Serv Pneumol, Creteil, France
[12] CHRU Tours, Serv Pneumol, Hop Bretonneau, Tours, France
[13] Sir Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Australia
[14] Clalit Hlth Serv, Inst Oncol, Tel Aviv, Israel
[15] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia
[16] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Dept Med Oncol, Brussels, Belgium
[17] AstraZeneca, Cambridge, England
[18] AstraZeneca, Gaithersburg, MD USA
[19] Astrazeneca, Paris, France
[20] Inst Curie, Inst Thorax, Paris, France
[21] Montsouris, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
79MO
引用
收藏
页码：S738 / S739
页数：2
相关论文
共 50 条
  • [21] Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy
    Oh, H. -J.
    Park, C. -K.
    Kim, Y. -C.
    Kim, Y. -H.
    Ahn, S. -J.
    Jeong, W. G.
    Lee, J. Y.
    Lee, J. C.
    Choi, C. M.
    Ji, W.
    Song, S. Y.
    Choi, J.
    Lee, S. Y.
    Kim, H.
    Lee, S. Y.
    Park, J.
    Yoon, S. H.
    Joo, J. H.
    Oh, I. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S294 - S295
  • [22] Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC
    Huang, Y.
    Zhao, J.
    Soon, Y. Y.
    Wong, A.
    Ang, Y.
    Asokumaran, Y.
    Low, J. L.
    Lee, M.
    Choo, J.
    Chan, G.
    Kee, A.
    Tay, S. H.
    Goh, B. C.
    Soo, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1044 - S1044
  • [23] Real-World Outcomes of Stage III NSCLC Treated with Chemoradiation plus /- durvalumab
    Duan, R.
    Kordon, A.
    Kwan, M.
    Yadav, P.
    Thomas, T. O.
    Abazeed, M.
    Gharzai, L. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E11 - E11
  • [24] PACIFIC-6: A Phase II Study of Durvalumab after sequential Chemoradiotherapy in Patients with unresectable Stage III NSCLC
    Wuerschmidt, F.
    Garassino, M.
    Faivre-Finn, C.
    Mazieres, J.
    Emeribe, U.
    Franks, A.
    Trunova, N.
    Reck, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S88 - S88
  • [25] Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
    Mehra, Ranee
    Yong, Candice
    Seal, Brian
    van Keep, Marjolijn
    Raad, Angie
    Zhang, Yiduo
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (02): : 153 - +
  • [26] Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
    Vansteenkiste, Johan F.
    Naidoo, Jarushka
    Faivre-Finn, Corinne
    Ozguroglu, Mustafa
    Villegas, Augusto
    Daniel, Davey
    Murakami, Shuji
    Hui, Rina
    Lee, Ki Hyeong
    Cho, Byoung Chul
    Kubota, Kaoru
    Broadhurst, Helen
    Wadsworth, Catherine
    Newton, Michael
    Thiyagarajah, Piruntha
    Antonia, Scott J.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (03):
  • [27] Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
    Garassino, Marina C.
    Mazieres, Julien
    Reck, Martin
    Chouaid, Christos
    Bischoff, Helge
    Reinmuth, Niels
    Cove-Smith, Laura
    Mansy, Talal
    Cortinovis, Diego
    Migliorino, Maria R.
    Delmonte, Angelo
    Garcia Sanchez, Jose
    Chara Velarde, Luis Enrique
    Bernabe, Reyes
    Paz-Ares, Luis
    Perez, Ignacio Diaz
    Trunova, Nataliya
    Foroutanpour, Kayhan
    Faivre-Finn, Corinne
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (12) : 1415 - 1427
  • [28] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
    Julian Taugner
    Lukas Käsmann
    Chukwuka Eze
    Alexander Rühle
    Amanda Tufman
    Niels Reinmuth
    Thomas Duell
    Claus Belka
    Farkhad Manapov
    Investigational New Drugs, 2021, 39 : 1189 - 1196
  • [29] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
    Taugner, Julian
    Kaesmann, Lukas
    Eze, Chukwuka
    Ruehle, Alexander
    Tufman, Amanda
    Reinmuth, Niels
    Duell, Thomas
    Belka, Claus
    Manapov, Farkhad
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1189 - 1196
  • [30] Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Pabani, A.
    Bebb, G.
    Cheung, W.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S282 - S283
12345